Followers | 84 |
Posts | 12534 |
Boards Moderated | 0 |
Alias Born | 07/25/2008 |
Monday, January 15, 2018 7:44:23 AM
Difference In Efficacy Between Men and Women
In the sub-set analysis presented by Dr. Solomon, there was an interesting sex difference. Albeit there were a very small number of men in the entire study (35 males out of 265 patients), women achieved a 36% CR rate in the low dose arm compared to 26% in the high dose arm. However, men achieved a 15% CR rate in the low dose arm versus a 43% CR rate in the high dose arm.
A In the sub-set analysis presented by Dr. Solomon, there was an interesting sex difference. Albeit there were a very small number of men in the entire study (35 males out of 265 patients), women achieved a 36% CR rate in the low dose arm compared to 26% in the high dose arm. However, men achieved a 15% CR rate in the low dose arm versus a 43% CR rate in the high dose arm.
Perform a do over to do a Phase 3b trial to determine dosages for men and women? Or, get the label right for women first??
Perplexing results to say the least.. may be a phase 3b trial will be needed to stratify the results? Or, approve for women first, then a phase 3b trial for men to optimize the dose? FDA to pull out their hair on this one???
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:56:55 PM
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference • Business Wire • 09/13/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:08:25 PM
- Aurinia Announces Board Restructuring • Business Wire • 09/12/2024 08:05:00 PM
- Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial • Business Wire • 09/05/2024 10:00:00 AM
- Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 08/28/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 10:07:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:03:38 AM
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results • Business Wire • 08/01/2024 10:00:00 AM
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 • Business Wire • 07/19/2024 10:00:00 AM
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
- Aurinia Announces 2024 Annual General Meeting Results • Business Wire • 06/14/2024 04:16:00 PM
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 • Business Wire • 05/14/2024 10:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM